menu
    • menu
    [{"orgOrder":0,"company":"Neopharm Labs Inc","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UroGen Pharma Announces License and Supply Agreement with Neopharm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Neopharm Labs Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"Neopharm Labs Inc \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"Neopharm Labs Inc \/ Neopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Neopharm Labs Inc

    Menu

    Neopharm Labs Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neopharm Labs Inc

                            Canada arrow
                            FNCE 2024
                            Not Confirmed

                            Neopharm Labs Inc

                            Canada arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : UroGen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            UroGen Pharma Announces License and Supply Agreement with Neopharm

                            Details : Neopharm will lead the regulatory process in Israel, which is supported by the results from the Phase 3 OLYMPUS trial that showed Jelmyto achieved clinically significant disease eradication in adults with LG-UTUC.

                            Brand Name : Jelmyto

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 28, 2021

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : UroGen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth